On August 13, a federal appeals court ruled in favor of Gilead Sciences, Inc. (NASDAQ:GILD), upholding a preliminary injunction that bars the defendants from importing or facilitating the sale of foreign-market Gilead-branded medications in the US. The US Court of Appeals for the Fourth Circuit found that the differences between Gilead’s HIV medication for the US market and the foreign versions being imported were “material, not theoretical.” The controversy began in December 2024 when Gilead Sciences, Inc. (NASDAQ:GILD) filed suit against a number of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its best-selling HIV drug Biktarvy.
How the Case Got Here
The dispute dates back to December 2024, when Gilead Sciences, Inc. sued a group of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its top-selling HIV drug Biktarvy. The lawsuit arose from a specific instance in which a patient in Maryland received the medicine in the mail from Turkey, with label instructions written in Turkish.
A federal district court in Baltimore ruled in Gilead’s favor and ordered a preliminary injunction, determining that the company was likely to succeed on its Lanham Act trademark violation and unfair competition arguments. As the case continued, the injunction was increased to include new sellers like CanaRx, ElectRx, and ScriptSourcing. The defendants filed an appeal with the Fourth Circuit, and the district judge declined to suspend the injunction while the appeal was pending, thus the import restriction has been in effect the entire time. The recent ruling maintains the order rather than overturning it.
The Core Legal Dispute
In court documents, Rx Valet stated that the Turkish-sourced Biktarvy was chemically identical to the US version, which was offered at a significantly higher price. Meritain, for its part, said that it has never supported getting non-FDA-approved pharmaceuticals from outside the US and denies the claims, despite being named as a defendant.
The Fourth Circuit rejected the defendants’ main argument that the imported and domestic versions of Biktarvy are interchangeable. The court’s judgment that the two versions differ materially, not just in packaging or labeling, but also in the quality-control protocols that each version goes through before reaching a patient, challenges the basic argument that these alternative funding programs have used to support their business model.
A Gilead Sciences, Inc. representative described the decision as a patient-safety victory, claiming that it improves patient safety by prohibiting medications that lack FDA monitoring and quality controls from accessing the US supply chain. Patient advocacy groups, many of which wrote amicus briefs in support of Gilead Sciences, Inc. during the appeal, praised the decision in similar words.
Institutional Sentiment
Hedge fund ownership in Gilead Sciences, Inc. decreased slightly from 77 funds in the first quarter of 2026 to 76 funds in the second quarter, while short interest stands at a modest 1.97% of the float, hinting at limited bearish sentiment against the stock prior to the ruling.
Legal Win Protects Biktarvy, but Pricing Pressure Remains
The case for Gilead Sciences, Inc. is based on a legal precedent that safeguards one of its most crucial revenue bringers. Biktarvy is a blockbuster HIV medicine, and a business model of importing cheaper foreign-market versions directly challenges its pricing power in the United States. The Fourth Circuit’s rejection of the equivalency argument provides Gilead Sciences, Inc., and by extension other drugmakers, with favorable Fourth Circuit precedent for challenging similar import programs.
Legal commentators have emphasized that the ruling doesn’t necessarily apply to every international sourcing arrangement, therefore some alternative funding programs may still be able to operate in ways that withstand similar legal scrutiny. The root cause that sparked the dispute in the first place, employer health plans and third-party administrators looking for lower-cost alternatives to high-priced US pharmaceuticals, has yet to be resolved, and pricing pressure on branded drugs like Biktarvy is likely to endure even after this legal win.
Insider Monkey’s Bottom Line
The court ruling is a clear near-term legal triumph for Gilead Sciences, Inc., as it removes uncertainty about a specific and growing risk to its HIV franchise revenue. Investors should see this as less of a trigger that changes Gilead’s prospects and more as a risk removed, preserving existing revenue rather than generating additional upside. The bigger long-term question, whether US drug pricing pressure eventually forces a different outcome than court rulings, remains unanswered, and investors should keep an eye on whether other drugmakers cite this case in their own litigation as a sign of how long this legal protection lasts across the industry.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
